Man Group
PTGX icon

Man Group’s Protagonist Therapeutics PTGX Stock Holding History

Man Group’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-34,013
Closed -$1.88M – 2417
2025
Q2 		$1.88M Sell
34,013
-94,593
-74% -$4.54M ﹤0.01% 1438
2025
Q1 		$6.22M Sell
128,606
-29,357
-19% -$1.23M 0.02% 925
2024
Q4 		$6.1M Buy
157,963
+102,132
+183% +$4.45M 0.02% 944
2024
Q3 		$2.51M Buy
55,831
+48,176
+629% +$1.95M 0.01% 1243
2024
Q2 		$265K Buy
+7,655
New +$224K ﹤0.01% 1817
2023
Q1 		– Sell
-94,070
Closed -$1.03M – 2212
2022
Q4 		$1.03M Buy
94,070
+14,135
+18% +$119K ﹤0.01% 1316
2022
Q3 		$674K Buy
+79,935
New +$756K ﹤0.01% 1414
2022
Q2 		– Hold
0
– – – 1889
2018
Q3 		– Sell
-86,126
Closed -$579K – 2197
2018
Q2 		$579K Buy
+86,126
New +$661K ﹤0.01% 1769

Other funds holding PTGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

Man Group's PTGX Position: Q3 2025 in Review

Man Group sold out of Protagonist Therapeutics (PTGX) in Q3 2025, closing a stake of 34,013 shares — an estimated $1.88M sold.

Man Group first reported a position in PTGX in Q2 2018 and held it in 8 quarters. The position peaked at $6.22M in Q1 2025. 274 funds tracked by Wall St. Rank hold PTGX as of Q3 2025.

  • Man Group reported no remaining Protagonist Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Man Group sold 34,013 Protagonist Therapeutics shares in Q3 2025, an estimated $1.88M.
  • Man Group first reported a position in Protagonist Therapeutics in Q2 2018 and held it in 8 quarters.
  • Man Group's Protagonist Therapeutics position peaked at $6.22M in Q1 2025.
  • 274 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2025.

Based on Man Group's 13F filing for Q3 2025, filed 14 Nov 2025.